The sponsors of two investigational products were due to appear before the European Medicines Agency this week to explain why their drugs that are in the final stages of regulatory review should be recommended for pan-EU marketing approval.
Amryt Pharmaceuticals was to make its case at an oral explanation meeting with the EMA for Filsuvez, its birch...






